Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2022 | 2021 | 2019 | 2018 | 2017
Number of items: 7.

2022

Kaddu-Mulindwa, Dominic, Altmann, Bettina, Robrecht, Sandra, Ziepert, Morita, Regitz, Evi, Tausch, Eugen, Held, Gerhard, Poeschel, Viola, Lesan, Vadim, Bittenbring, Joerg Thomas ORCID: 0000-0003-3864-8315, Thurner, Lorenz, Pfreundschuht, Michael, Christofyllakis, Konstantinos ORCID: 0000-0002-0308-388X, Truemper, Lorenz, Loeffler, Markus, Schmitz, Norbert, Hoth, Markus ORCID: 0000-0001-7080-4643, Hallek, Michael ORCID: 0000-0002-7425-4455, Fischer, Kirsten, Stilgenbauer, Stephan, Bewarder, Moritz and Rixecker, Torben Millard (2022). KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Lancet Haematol., 9 (2). S. E133 - 10. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

2021

Frontzek, Fabian ORCID: 0000-0003-1705-3638, Ziepert, Marita, Nickelsen, Maike, Altmann, Bettina, Glass, Bertram, Haenel, Mathias, Truemper, Lorenz, Held, Gerhard, Bentz, Martin, Borchmann, Peter, Dreyling, Martin, Viardot, Andreas, Kroschinsky, Frank P., Metzner, Bernd, Staiger, Annette M., Horn, Heike, Ott, German, Rosenwald, Andreas, Loeffler, Markus, Lenz, Georg and Schmitz, Norbert (2021). Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol., 8 (4). S. E267 - 11. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

2019

Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Borchmann, Peter, Viardot, Andreas, Soekler, Martin, Keller, Ulrich, Schmidt, Christian, Truemper, Lorenz, Mahlberg, Rolf, Marks, Reinhard, Hoeffkes, Heinz-Gert, Metzner, Bernd, Dierlamm, Judith, Frickhofen, Norbert, Haenel, Mathias, Neubauer, Andreas, Kneba, Michael, Merli, Francesco, Tucci, Alessandra ORCID: 0000-0003-3052-7463, Brown, Peter de Nully ORCID: 0000-0002-6522-4086, Federico, Massimo, Lengfelder, Eva, di Rocco, Alice, Trappe, Ralf ORCID: 0000-0001-7565-7160, Rosenwald, Andreas, Berdel, Christian, Maisenhoelder, Martin, Shpilberg, Ofer, Amam, Josif, Christofyllakis, Konstantinos ORCID: 0000-0002-0308-388X, Hartmann, Frank, Murawski, Niels, Stilgenbauer, Stephan, Nickelsen, Maike, Wulf, Gerald, Glass, Bertram, Schmitz, Norbert, Altmann, Bettina, Loeffler, Markus and Pfreundschuh, Michael (2019). Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet, 394 (10216). S. 2271 - 2282. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-547X

2018

Pfreundschuh, Michael, Murawski, Niels, Ziepert, Marita, Altmann, Bettina, Dreyling, Martin H., Borchmann, Peter, Luminari, Stefano, Witzens-Harig, Mathias, Dierlamm, Judith, Haenel, Mathias, Truemper, Lorenz, Metzner, Bernd, Lengfelder, Eva, Keller, Ulrich B., Ruebe, Christian, Berdel, Christian, Schmitz, Norbert, Held, Gerhard and Poeschel, Viola (2018). Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Altmann, Bettina, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Viardot, Andreas, Borchmann, Peter, Kanz, Lothar, Keller, Ulrich, Schmidt, Christian, Mahlberg, Rolf, Metzner, Bernd, Marks, Reinhard, Hoeffkes, Heinz-Gert, Christofyllakis, Konstantinos, Amam, Josif, Berdel, Christian, Stilgenbauer, Stephan, Schmitz, Norbert, Truemper, Lorenz, Murawski, Niels, Loeffler, Markus and Pfreundschuh, Michael (2018). Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

2017

Murawski, Niels, Miriam, Josif, Altmann, Bettina, Ziepert, Marita, Haenel, Mathias, Viardot, Andreas, Neubauer, Andreas, Held, Gerhard, Truemper, Lorenz, Schmidt, Christian, Kanz, Lothar, Hallek, Michael, Schmitz, Norbert, Heintges, Tobias, Koelbel, Christian, Poeschel, Viola and Pfreundschuh, Michael (2017). Anti-infective prophylaxis with aciclovir and cotrimoxazole to reduce the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy. J. Clin. Oncol., 35. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Pfreundschuh, Michael, Christofyllakis, Konstantinos, Altmann, Bettina, Ziepert, Marita, Haenel, Mathias, Viardot, Andreas, Neubauer, Andreas, Held, Gerhard, Truemper, Lorenz, Schmidt, Christian, Kanz, Lothar, Hallek, Michael J., Schmitz, Norbert, Heintges, Tobias, Koelbel, Christian, Schneider, Guenther, Ruebe, Christian, Hellwig, Dirk ORCID: 0000-0002-3056-0143, Poeschel, Viola and Murawski, Niels (2017). Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL > 60 study of the DSHNHL. J. Clin. Oncol., 35. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

This list was generated on Sun Nov 24 02:19:04 2024 CET.